Carla Coffin
cscoffin@ucalgary.ca
In-person interactions impact on HCV, HIV, and Syphilis Rates in At Risk Populations
Pam Ford
Targeting the hepatitis B virus covalently closed circular DNA genome using a G-quadruplex specific single domain antibody
Simmone D'Souza
HDV is uncommon in Toronto but can have an aggressive clinical course: interim analysis
David Wong
Biologiste Médical
Ronald Simeon
Impact of COVID-19 pandemic–related measures on testing for hepatitis B in British Columbia, Canada: an interrupted time series analysis
Richard Morrow
Clinical Science Advances in Hepatitis B (HDV, HCV, HIV Co-infections): A Comprehensive Review
Moses Donkor
Epidemiology and Public Health Implications of Hepatitis B, HDV, HCV, and HIV Co-infections
Desmond Osei
EPIDEMIOLOGY, TREATMENT PATTERN, AND SURVIVAL IN CANADIAN PATIENTS WITH CHRONIC HEPATITIS B RELATED HEPATOCELLULAR CARCINOMA
Yashasavi Sachar
HCC RISK STRATIFICATION USING RANDOM SURVIVAL FORREST MACHINE LEARNING MODEL OUTPERFORMS TRADITIONAL ANALOG SCORING
Yashasavi Sachar
Hepatitis B core antibody is associated with liver fibrosis in people with HIV independently of MASLD
Dong Hyun (Danny) Kim
Initial HBV-Hepatocyte Genomic Integrations, Their Formation and Potential Role in Oncogenesis
Thomas Michalak
Investigating HDV screening rates and associated demographic characteristics among first-time HBV positive patients in Alberta from 2018-2022
Alexa Thompson
Compassionate use of REP 2139-Mg in HBV / HDV / HIV co-infection: a first Canadian experience
Sébastien Poulin
Functional cure of chronic HBV infection
David Wong
Using discrete field documentation in Epic EMR for clinical research of hepatitis B
David Wong
A DNA knot not like any other - exploring the specificity of HBV’s promoter G4-quadruplex
Archee Panwar
Intravital Imaging of the Liver Microenvironment in The Woodchuck Model of Hepatitis B Virus Infection
Layla Al-Yasiri
Chronic HBV infection in Toronto, Canada: Tale of two clinics
David Wong
Demographic Characteristics of Hepatitis B-Infected Sub-Saharan African Immigrants in Canada.
Nana Frimpong
Determining a Hepatitis Delta virus (HDV) peptidomimetic therapeutic to target Hepatitis B virus (HBV)
Justine Beghin
Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs
Samantha Polege
Epidemiology and Natural History of Chronic Hepatitis B in the Canadian Province of Alberta from 2012 to 2021: A Population-based Study
Golasa Samadi Kochaksaraei
Epidemiology, Linkage to Care and Natural History of Women of Childbearing Age with Chronic Hepatitis B: A Population-based Study
Golasa Samadi Kochaksaraei
Defining a Hepatitis D Virus Antibody Testing Algorithm for Accurate Screening
Carla Osiowy
IL-2 Produced by HBV-specific T cells as a Biomarker of Viral Control and Predictor of Response to PD-1 Therapy Across Clinical Phases of Chronic Hepa
Loghman Salimzadeh
Next Generation Sequence (NGS) Analysis for Hepatitis B Virus (HBV) Outbreak Transmission Analysis in Manitoba
Carla Osiowy
Prevalence and Clinical Characteristics of Hepatitis Delta Virus (HDV) Infected Individuals in British Columbia
Valeriya Zaborska
PSMA-Targeted Radionuclide Therapy of Hepatocellular Carcinoma in a Woodchuck Model
Hoda Poorbagher
G4Q-binding ligands: a starting point for potential cure therapies for chronic hepatitis B infections
Jessica Skoreyko
Cracking the HBV Code: Unravelling the specificity of SP1 with G-Quadruplex for next- generation cccDNA inhibitors
Kuldeep Kaur
Effect of HBV treatment on all-cause and liver-related death among individuals with HBV and cirrhosis in British Columbia: a population-based cohort
Jean Makuza
Hepatitis B Virus Genotype (GT) Does Not Influence Virological and Enzymatic Measures Over Time
Curtis Cooper
Prevalence of Hepatitis B Among Adults Receiving Immunosuppressive Therapy At a Tertiary Care Center in Saudi Arabia
Abdulrhman Alamr
Hepatocellular carcinoma (HCC) in patients followed in two clinics in Toronto
David Wong
Experience of a Chinese Hepatitis B Peer Support Group (PSG): Successes and Challenges
Colina Yim
Small molecules approach in HBV treatment:preventing transcription in the pre-core promoter by blocking a G-quadruplex with mithramycin and daunorubin
Kira Sviderskaia
Kinetics of Quantitative HBsAg Decline in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Antiviral Therapy
Frank Hyun
Opening the X-files: Exploring HBx protein’s role in transcriptional enhancement
Emma Kasinyabo
Establishment of HBx responsive quantitative cell culture reporter system for monitoring HBV infection
Muhammad Atif Zahoor
Unravelling an important DNA knot – analysis of HBV’s promoter G4-quadruplex
Mohaddeseh Pakzamir
Production of recombinant woodchuck surface antigen and antibodies for use in ELISAs, ELISpots, and western blots
Michelle Tang
Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs
Samantha Polege
Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.
Nikolas Shapka
Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.
Nikolas Shapka
David Wong
Under Review
Profile Summary
| Submission ID | PRO7B6CC2ME |
|---|---|
| Name | David Wong |
| Call | Progress toward Hepatitis B Elimination Meeting in Canada - Abstract Submission |
| Email Address | dave.wong@uhn.ca |
| Title | Hepatologist |
| Organization | University Health Network |
| State/Province | Ontario |
| City | Toronto |
Session
| Title | HDV is uncommon in Toronto but can have an aggressive clinical course: interim analysis |
|---|---|
| Description | Background: Retrospective studies suggest that HDV might co-infect 4.5-13% of those with chronic HBV infection. However, retrospective studies might be biased to over-estimate the prevalence of HDV. Purpose: Explore the effect of universal screening for HDV in those with chronic HBV infection in Toronto. Method: Universal screening for HDV started after CLM in March 2023. Epic EMR was adopted in our clinic on June 4, 2022. Taking advantage of discrete data field documentation, we tracked HBV-HDV status using ICD-10 codes: B18.19 for chronic HBV infection, HDV status was unknown; B17.0 for HDV-HBV co-infection; B18.10 for chronic HBV infection, HDV negative. Result(s): From June 6, 2022 to Jun 9, 2023, N=2,577 individual patients have been assessed. N=11 were HDV+ (3 resolved), N= 553 were HBV+HDV-, N=590 were HBV+ but HDV unknown. All HDV+ cases were identified from targeted testing. Conclusion(s): HDV is uncommon in Toronto – 8/561 (1.4%). To date, no new cases of HDV have been identified through universal screening. |
| Track | Hepatitis B (including HDV, HCV, HIV Co-infections) - Clinical Science |
| Formats | |
| Audiences |
Files
| 850733_CASL_-_D_Wong_Hepatitis_D_Jun_25_2023.docx | HDV is uncommon in Toronto but can have an aggressive clinical course: interim analysis |
|---|
Submit Review
Is this abstract accepted for a poster presentation? *
Is this abstract accepted for a trainee travel grant?